- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05600842
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
April 25, 2024 updated by: Allen Chen, University of California, Irvine
This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
111
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chao Family Comprehensive Cancer Center University of California, Irvine
- Phone Number: 877-827-8839
- Email: ucstudy@uci.edu
Study Contact Backup
- Name: University of California Irvine Medical
Study Locations
-
-
California
-
Orange, California, United States, 92868
- Recruiting
- Chao Family Comprehensive Cancer Center, University of California, Irvine
-
Contact:
- Allen M Chen, MD
- Phone Number: 877-827-8839
- Email: ucstudy@uci.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with HPV-positive oropharyngeal cancer
Description
Inclusion Criteria:
- Pathologically (histologically or cytologically) proven (from primary lesion and/or lymph nodes) diagnosis of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry. Numerous studies have demonstrated near 100% agreement between p16 and HPV for patients with oropharyngeal cancer. As such, the use of p16 has been accepted as an appropriate surrogate for HPV status.
- Clinical stage I, II, or III disease (AJCC Eighth Edition); Note: Patients with M1 tumors (distant metastases) are not eligible;
- History/physical examination within 6 weeks prior to registration, including assessment of weight and recent weight loss;
- Age ≥ 18;
- PET/CT within 6 weeks prior to registration;
- Patients must sign a study-specific informed consent form prior to study entry.
- Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.
Exclusion Criteria:
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years;
- Patients who have had initial surgical treatment other than the diagnostic biopsy of the primary site or nodal sampling of the neck disease are excluded;
- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable;
- Receipt of prior radiotherapy that would result in overlap with proposed field.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
De-escalated radiotherapy
|
IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week.
High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-Year Progression-Free Survival
Time Frame: Given the natural history of this disease, PFS will be monitored up to 2 years from registration
|
Progression-free survival (PFS) is defined as the time from registration to disease progression or death from any cause.
|
Given the natural history of this disease, PFS will be monitored up to 2 years from registration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Given the natural history of this disease, overall survival will be monitored for up to 2 years from registration
|
Survival time will be measured from the date of randomization to the date of death due to any cause or last follow-up.
|
Given the natural history of this disease, overall survival will be monitored for up to 2 years from registration
|
Local-regional control
Time Frame: Given the natural history of this disease, local-regional control will be monitored up to 2 years from registration
|
Local-regional control is defined as the absence of local and/or regional progression.
|
Given the natural history of this disease, local-regional control will be monitored up to 2 years from registration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Allen M Chen, MD, Chao Family Comprehensive Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 3, 2022
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
November 1, 2026
Study Registration Dates
First Submitted
October 26, 2022
First Submitted That Met QC Criteria
October 26, 2022
First Posted (Actual)
November 1, 2022
Study Record Updates
Last Update Posted (Estimated)
April 26, 2024
Last Update Submitted That Met QC Criteria
April 25, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2048 (University of California, Irvine)
- UCI 22-132 (Other Identifier: CFCCC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV Positive Oropharyngeal Squamous Cell Carcinoma
-
Jonathan Schoenfeld, MD, MPHNaverisRecruitingHPV Positive Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterAstraZenecaTerminatedOropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologySuspendedOropharyngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Basaloid Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Papillary Squamous Cell Carcinoma | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditionsUnited States, Canada
-
Jonsson Comprehensive Cancer CenterEli Lilly and CompanyTerminatedClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage IV HPV-Mediated (p16-Positive)... and other conditionsUnited States
-
University of ArizonaNational Cancer Institute (NCI)TerminatedHPV Positive Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | CDKN2A-p16 Positive | Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7 | Stage II Oropharyngeal Squamous Cell Carcinoma...United States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingOropharyngeal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Cue BiopharmaMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Icahn School of Medicine at Mount SinaiRecruitingHPV-positive Oropharyngeal Squamous Cell CarcinomaUnited States
Clinical Trials on Intensity-Modulated Radiation Therapy (IMRT)
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
St. Jude Children's Research HospitalMayo ClinicTerminatedAbdominal NeuroblastomaUnited States
-
Washington University School of MedicineRecruitingEndometrial CancerUnited States
-
Washington University School of MedicineActive, not recruiting
-
NYU Langone HealthCompleted
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Cognitive/Functional EffectsUnited States, Canada
-
M.D. Anderson Cancer CenterCompletedLung Cancer | MesotheliomaUnited States
-
Stanford UniversityVarian Medical SystemsCompletedHead and Neck CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingSquamous Cell Carcinoma of Head and NeckUnited States